a vaccine development company focusing on a second-generation Covid-19 vaccine, has partnered with Exothera S.A. to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials.
Exothera will finetune the industrialization of the FINCOVAC 2.0 process and manufacture clinical material for Phase I/II trials. FINCoVac 2.0 is designed to address the most critical current coronavirus variants and it is based on adenoviral vector gene transfer technology. The FINCoVac vaccine is designed to program the nasopharyngeal cells to produce an immune response-inducing modified SARS-CoV-2-viral spike protein. FINCoVac 2.0 represents an easy-to-administer booster for those who are already fully vaccinated with other coronavirus vaccines.
Exothera specializes in the industrialization of vaccine and gene therapy processes with deep knowledge of modern scalable bioreactors, downstream process technologies and GMP manufacturing. Exothera offers a full-service model where it manages all the elements of the product development value chain, from process development to manufacturing. This single partner approach will allow Rokote Laboratories to enter clinical trials more quickly.
Hanna Lesch, chief technology officer at Exothera, said,
